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Abstract Aortic stenosis (AS) is the most common primary
valve disorder in the elderly with an increasing prevalence;
transcatheter aortic valve implantation (TAVI) has become an
accepted alternative to surgical aortic valve replacement
(AVR) in the high risk or inoperable patient. Appropriate se-
lection of patients for TAVI is crucial and requires a multidis-
ciplinary approach including cardiothoracic surgeons, inter-
ventional cardiologists, anaesthetists, imaging experts and
specialist nurses. Multimodality imaging including echocardi-
ography, CT and MRI plays a pivotal role in the selection and
planning process; however, echocardiography remains the pri-
mary imaging modality used for patient selection, intra-
procedural guidance, post-procedural assessment and long-
term follow-up. The contribution that contemporary transtho-
racic and transoesophageal echocardiography make to the se-
lection and planning of TAVI is described in this article.
Keywords Aortic stenosis . Transcatheter aortic valve
implantation . Echocardiography
Introduction
Aortic stenosis is the commonest left-sided valve lesion [1] and
affects 12.4 % of patients over the age of 75 [2]. Severe aortic
stenosis is present in 3.4 % of patients [2]. The most frequent
aetiology is calcification of a normal tri-leaflet valve or second-
ary to a congenital bicuspid valve [3–5], which has a prevalence
of 1 % [6]. Rheumatic aortic stenosis is less prevalent in the
developed world, although it remains a common cause of mor-
tality in more economically challenged regions. The prognosis
in patients with symptomatic aortic stenosis is poor, with the
interval from the onset of symptoms to the time of death being
approximately 2 years in individuals with heart failure, 3 years
in those with syncope and 5 years in those with angina [7].
Severe aortic stenosis is conventionally defined as a peak
aortic velocity >4 m/s, a mean gradient >40 mmHg and a
valve area <1 cm2 [8••]. Class I indications for aortic valve
replacement are symptomatic severe aortic stenosis, asymp-
tomatic patients with severe aortic stenosis and left ventricular
ejection fraction <50 % and patients with severe aortic steno-
sis undergoing cardiac surgery for other indications [8••].
The majority of aortic valve replacements are surgical aor-
tic valve replacement (AVR). However, in high-risk patient
groups, factors such as increasing age, prior cardiac surgery
and other co-morbidities, such as heart failure, respiratory and
renal diseases, are associated with a high potential for opera-
tive mortality and morbidity [9, 10]. AVR has historically
been less frequently performed in these patients [11], and
hence, one third of patients with symptomatic aortic stenosis
have in the past been denied surgical intervention [12].
Transcatheter aortic valve implantation (TAVI) was first
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performed in 2002 as a less invasive approach [13] and is now
recommended as an alternative strategy for patients in high-
risk surgical groups [14]. This practice is supported by clear
randomised trial evidence demonstrating superiority over
medical treatment and equivalence to conventional surgery
in high-risk subgroups [7, 15, 16•, 17]. The ongoing
Placement of AoRTic TraNscathetER Valve (PARTNER) II
trial will assess an intermediate risk cohort comparing TAVI
versus surgical AVR in a randomised 1:1 fashion [18].
TAVI was initially performed almost exclusively under
general anaesthesia, and transoesphageal echocardiography
was an integral guide for the pre-operative procedure.
Recent years have seen an increasing trend for performing
the procedure under conscious sedation, and the role of echo
has evolved, so now, it plays a major role in case selection and
procedure planning, with an increasing emphasis on transtho-
racic echocardiography (TTE).
Echocardiography Guidance to Case Selection
for TAVI
(a) Severity of aortic stenosis
Aortic stenosis is a disease both of the valve and the ven-
tricular response to the chronic afterload circumstance. The
classical definition of severe aortic stenosis is still reflected
in the current guidelines, that is a Vmax >4 m/s, mean gradient
>40 mmHg and AVA <1 cm2, in the presence of preserved left
ventricular function [8••]. When indexed for body surface
area, a valve area of 0.6 cm2/m2 is also considered the thresh-
old for severe aortic stenosis (AS). This is conventionally
described as high-gradient aortic stenosis (HGAS).
However, the myocardial response may develop in a way that
results in reduced flow through the valve; this results in a
significantly lower transvalvular gradient into the ‘moderate’
or even ‘mild’ range. Situations where the aortic valve gradi-
ents suggest a lesser severity of aortic stenosis than the valve
area are very common [19], and this may be due to a low
stroke volume in patients with either a dilated left ventricle
and reduced ejection fraction (low-flow, low-gradient AS
(LFLGAS)), or where there is excessive hypertrophy leading
to a small ventricular cavity size with normal ejection fraction
[20], but reduced stroke volume (paradoxical low-flow aortic
stenosis (PLFLGAS)).
These low-gradient patients may have truly severe AS;
alternatively, the reduction of flow may be the cause of the
low valve area, so-called pseudo severe AS. This is a critical
distinction because in true severe AS, intervention on the aor-
tic valve is likely to result in clinical improvement, whereas if
the problem primarily lies at the level of the myocardium, this
is less likely.
Sorting these discrepant results out requires the integration
of echocardiography, other imaging modalities and
good clinical sense. Evaluation starts with a visual assessment
of the structure, calcification and mobility of the aortic valve.
A relatively mobile valve is unlikely to represent severe aortic
stenosis no matter what the Doppler calculations demonstrate.
In patients with impaired ejection fraction, increasing flow
through the valve using dobutamine stress echo (DSE) is well
established and has been recommended as a class IIa indica-
tion in managing patients with valvular heart disease [8••, 14].
If a 20 % increase in stroke volume is associated with the
development of a gradient of 40 mmHg or a peak velocity
of greater than 4 m/s, with an unchanging valve area, then,
the AS is severe and intervention is warranted.
In PLFLGAS, the situation is more complex and measure-
ment errors are more frequent. Even when measurements are
made correctly, the anatomy of the outflow tract may cause
significant variability. The anteroposterior dimension of the
left ventricular outflow tract (LVOT) used in calculating the
aortic valve area using the continuity equation is susceptible to
measurement error, and the effect of this is amplified as the
measurement is squared to describe the LVOT area [21]. Not
only that, the LVOT is rarely circular with the aortic prosthesis
(AP) dimension often being the minor dimension [22].
Confirming normal flow through the valve (>35 mls/m2)
makes significant AS unlikely, but where the clinical situation
remains unclear, either DSE or cardiac CT to evaluate the
calcium score of the aortic valve is helpful [23].
Whilst there is clear evidence of benefit from TAVI in pa-
tients with HGAS, TAVI may be an attractive option in the
patients with low-gradient, low ejection fraction aortic steno-
sis, comparedwith surgical AVR [24]. The procedure has been
associated with enhanced recovery in patients with reduced
ejection fraction [25]. There is limited data as to whether pa-
tients with paradoxical low-flow aortic stenosis will benefit
from TAVI [26, 27, 28•]. A study by Sullivan et al. showed
that symptomatic patients with paradoxical low-flow aortic
stenosis demonstrated a functional improvement at 1-year
post-TAVI. Patients with low ejection fraction and low-flow
AS also had functional improvement 1-year post-TAVI, al-
though the left ventricular (LV) function improvement, al-
though significant, was less than that observed with high-
gradient aortic stenosis [29].
Although post-procedure outcome is generally worse in the
low-gradient, low-flow groups, survival is still improved with
TAVI compared to medical management and is similar with
TAVI and surgical AVR, in patients with paradoxical low-flow
aortic stenosis. TAVI reduced 1-year mortality from 66 to
35 %, in these patients [26]. Data from the German TAVI
registry found that in high-risk patients with low-gradient se-
vere AS, TAVI associated with a significantly higher mortality
at 30 days and at 1 year, although long-term survivors did
benefit from functional improvement and improved quality
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of life [29]. Low-flow, low-gradient aortic stenosis has a strong
impact on 6-month and 1-year mortality; however, there are
considerable haemodynamic and clinical improvements.
Therefore, it is important to weigh up the risks and benefits of
TAVI in every patient with low-flow aortic stenosis [30].
(b) Aortic valve cusp anatomy
Imaging assessment of the number and arrangement of
cusps prior to TAVI is essential. The asymmetry of the annular
ring of a bicuspid valve can result in an elliptical annular shape
with associated eccentric calcium distribution [31]. The TAVI
prosthesis may, therefore, not expand fully, leading to pros-
thesis misplacement and paravalvular regurgitation [32].
Dilatation of the ascending aorta is also common in patients
with bicuspid aortic valves [33], and TAVI may therefore be
associated with an increased risk of aortic dissection [34]. The
PARTNER trial excluded all patients with bicuspid aortic
valves, as there was concern that the valve may distort the
prosthesis, leading to significant paravalvular regurgitation
[7]. There have, however, been multiple descriptions of suc-
cessful TAVI in bicuspid severe AS [35].
A study carried out byWijesinghe in a cohort of 11 patients
with bicuspid severe aortic stenosis undergoing TAVI showed
an improvement in valve area and mean gradient. Two pa-
tients were found to have moderate paravalvular aortic regur-
gitation and one patient required surgery for valve migration,
over a 30-day follow-up period [36]. Phan et al. carried out a
systematic review and meta-analysis on 149 patients undergo-
ing TAVI. They found no difference in 30-day mortality, post-
TAVI gradients, moderate to severe paravalvular AR, bleeding
or vascular complications in patients with bicuspid valves,
suggesting that TAVI is feasible in these patients [37•].
The results of the German TAVI registry showed that there
was an increased rate of paravalvular aortic regurgitation in pa-
tients with bicuspid compared to tricuspid aortic valves (25 vs
15 %, p=0.05), although the 30-day or 1-year mortality was not
elevated [38]. The Poland National Registry investigators found
that the post-procedure mean transvalvular gradient, severity of
aortic regurgitation and 30-day and 1-year mortality were similar
between patients with bicuspid and tricuspid valves [39].
These results have encouraged an increasing number of op-
erators to undertake TAVI more freely in this group of patients,
and the presence of a bicuspid valve should be considered a risk
marker for complications and suboptimal deployment rather
than an absolute contraindication. Diagnosis of bicuspid anato-
my with 2D echocardiography is often challenging, and 3D
techniques are often needed to assess the elliptical geometry
of the annulus and for accurate dimension measurement.
Other factors in device selection include the presence or ab-
sence of a concomitant aortopathy and the location and domi-
nance of the coronary arteries, which are more likely to have
anatomic variations with bicuspid aortic valve disease [40].
(c) Mitral regurgitation
Patients with severe aortic stenosis may also have signifi-
cant mitral regurgitation (MR) [41], which is typically left
untreated in the TAVI population. There are multiple causes
of mitral regurgitation, and its mechanisms are due to an or-
ganic (due to a structurally abnormal valve) or functional
cause [42]. Patients with severe aortic stenosis have a high
prevalence of coronary artery disease, which may result in
ischaemic mitral regurgitation. End-stage aortic stenosis may
also lead to left ventricular dilatation, and these factors, along
with concomitant aortic regurgitation, can influence the pres-
ence and severity of functional MR [43].
Moderate to severe MR occurs in approximately 20 % of
patients undergoing TAVI, and its severity improves in around
50% of patients after the intervention, especially in those with
non-structural MR associated with adaptive changes in LV
geometry [44].
Studies of patients with severe MR suggested an increase in
early mortality after TAVI [43, 44], due to poor post-procedure
haemodynamics and heart failure, whilst other studies that in-
cluded patients with moderate or severe MR as part of the sig-
nificant MR group failed to show this association [45, 46]. With
regard to late mortality, patients with moderate or severe MR
had similar mortality rates compared to those with no or mild
MR [45]. In contrast to these results, with increasing grades of
MR severity, there was an increasing risk of 1-year mortality
from the German and Italian TAVI registries [47, 48].
(d) Pulmonary arterial hypertension and right ventricular
dysfunction
Pulmonary hypertension may be present in patients with
severe AS, due to transmission of increased left ventricular
diastolic or left atrial pressures, associated mitral regurgitation
or an increase in pulmonary vascular tone, which can result in
right heart failure. It is an accepted predictor of poor outcome
after surgical AVR, and there is growing evidence that pulmo-
nary hypertension and tricuspid regurgitation have an adverse
impact on prognosis in patients undergoing TAVI [49]. A re-
cent large study of 155 patients, however, showed that pre-
procedural right ventricular dysfunction did not adversely in-
fluence medium-term outcome following TAVI [50].
(e) Valve in valve TAVI
Redo surgery is the standard treatment for degenerative aortic
bioprostheses. This, however, carries an operative mortality risk
of 1.5–23 %, depending on patient age, number of previous op-
erations, left ventricular dysfunction and technical difficulties
caused by adhesions [51]. TAVI may be an attractive option in
thesehigh-risksurgicalpatients, and indicationsforvalve invalve
TAVI include bioprosthetic stenosis, regurgitation or both.
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Previous studies have confirmed the feasibility of valve
in valve TAVI for patients with failing bioprostheses
[52–54]. A registry of 202 patients undergoing valve in
valve TAVI showed that 84.1 % of patients reported an
improvement in symptoms and were NYHA functional
class I/II early after the procedure. However, a high rate
of device malposition, and elevated post-procedural gra-
dients, was observed. The relatively high malposition rate
may be secondary to the relative lack of valvular calcifi-
cation and, in some cases, difficulty in defining the opti-
mal target for implantation during the procedure, particu-
larly in stentless bioprostheses, in which no anatomic
markers are available [55].
Similar to the TAVI workup in patients with native AS,
patients being considered for valve in valve TAVI should un-
dergo imaging with TTE± transoesophageal (TOE) and CT.
Aortic root anatomy, coronary ostial position and the presence
of pannus and leaflet calcification should be identified [56].
Transcatheter heart valves are usually oversized to achieve
stability, prevent migration of the valve and to minimise
paravalvular regurgitation.
TAVI Procedure Planning
Once an assessment of the severity of aortic stenosis incorpo-
rating both valvular and other echocardiographic factors has
been performed, echo has an important role alongside other
imaging modalities, especially cardiac CT, in procedure plan-
ning. A multidisciplinary approach and the use of multiple
imaging modalities to fully delineate the anatomy of the aortic
valve, aorta and peripheral vasculature is essential.
Echocardiography has also played a major role intra-
procedurally and in follow-up [57]. This role has recently been
disputed by trial data that fails to show an outcome benefit nor
reduced risk associated with TOE guidance. Transoesophageal
echo measurement, as well as pre-procedure cardiac CT, may
have limitations in precise annular sizing; however, TOE may
be helpful in select cases. Balloon valvuloplasty during the pro-
cedure may also be used to assist in annular sizing and in device
selection [58].
(a) Distribution of calcium
Echocardiography is useful in demonstrating the presence
and distribution of calcium. Aortic valve calcification in-
creases the risk of gaps between the prosthesis and the native
valve, which can lead to paravalvular regurgitation, although a
degree of annular calcification is present in all patients with
degenerative aortic stenosis [59]. A large amount of calcifica-
tion at the edge of the native valvular leaflets may increase the
risk of coronary occlusion by displacement over the coronary
ostium. Furthermore, heavy calcification in the sinotubular
junction may cause restriction during balloon expansion at
the aortic end and consequently affects ventricular displace-
ment of the device at the time of deployment [60, 61]. A
higher incidence of post-procedure aortic regurgitation is seen
with significant annular and commissural calcification [62].
Extensive calcification especially in the subvalvular position
is one of the major predictors of annulus or sinus rupture
during implantation. The mechanisms are unclear and the
subvalvular areas appear to predict a higher risk, perhaps be-
cause valvular calcification can be accommodated within the
sinus of valsalva. Localised calcification at the valve tips is a
well recognised although rare cause of aortic rupture and
contained haematoma.
(b) Annulus size measurement
The aortic annulus is described as a virtual ring formed by
joining the basal attachments of the aortic cusps [63].
Accurate understanding of the anatomy of the aortic annulus
and measurement of the annular dimension is key as it deter-
mines eligibility for TAVI and guides the type and size of the
valve to be used. Implantation of an appropriately sized pros-
thesis will reduce the frequency of serious complications [64].
Underestimation of annular size can lead to selection and de-
ployment of a valve that is too small which can lead to prosthesis
migration and paravalvular regurgitation [65]. Overestimation
can lead to incomplete deployment, valvular and paravalvular
regurgitation or annular rupture, which has been described in
around 5 % of patients undergoing TAVI with a balloon-
expandable valve [66]. The objective is to deploy a valve of
sufficient size to reduce paraprosthetic regurgitation but not ex-
ceeding >20 % greater than the measured annulus, where rup-
tures and contained ruptures become much more common.
The annular AP diameter has traditionally been measured
in the long-axis view in systole at the hinge points of the
leaflets into the LVOT with a trailing edge to leading edge
convention. During TOE, a long-axis view (120–140°) is used
to measure the annular diameter in systole at the level of the
basal attachment of the valve cusps. 2D methods, however,
have their limitations in sizing, as a circular rather than an
elliptical annulus is assumed [61]. A 3D TOE study showed
that the LVOT is oval in shape in 90 % of patients [67]. There
is good reproducibility with all echocardiographic modalities
in aortic annulus measurement, the highest being with 3D
TOE. Measurements made by 3D techniques alter the choice
of prosthesis size and have proven superior for the prediction
of paravalvular AR than 2D TOE [68, 69].
Annulus measurements using 3D imaging with TOE, mul-
tislice CT and MRI have been studied and have been com-
pared to 2D echocardiography. CT- and TOE-based annular
measurements have been shown to both change valve sizing
strategy and have a higher predictive value than 2D TOE for
paravalvular AR [70–72]. When CT has been compared to 3D
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echocardiography, theywere both found to predict paravalvular
AR with equal accuracy [73]. Annulus diameters and areas for
pre-procedural TAVI assessment by 3D-TOE are significantly
smaller than multislice computer tomography (MSCT) with
exception of sagittal diameters. Using sagittal diameters, both
modalities predicted well final prosthesis size and excellent
procedural results were obtained. 3D-TOE can thus be a useful
alternative in patients with contraindications to MSCT [74].
On average, compared with CT, even 3D echo provides an
annular area of just under 0.5 cm2, which is significantly clos-
er than 2D echo but still allows for a potential discrepancy.
This difference must be borne in mind when valve sizing
using 3D echo which is sometimes required when CT is not
possible. By and large however, CT is the preferred method
for making this assessment.
(c) Root anatomy
Echocardiography also provides assessment of the relation-
ship of the coronary arteries to the annulus and valve leaflets.
Valve deployment should not compromise the coronary ostia,
either from the device itself or from cusp calcification that
may be shifted into the coronary arteries. The height of the
coronary ostia from the base of the aortic valve leaflets ideally
should be greater than 10 mm to prevent coronary arterial
occlusion on implantation of the prosthesis [75, 76]. The re-
lationship between the sinus capacity and valvular calcium
should always be carefully evaluated.
(d) Significant left ventricular upper septal hypertrophy has
traditionally been considered a relative contraindication to
TAVI because of the risk of maldeployment [77–79].
Severe left ventricular hypertrophy with apical oblitera-
tion may preclude transapical TAVI, whilst marked angu-
lation of the ascending aorta or aortic arch may be more
suited to transapical delivery of the prosthesis [80]. With
modern implantation techniques and valve choices, this is
rarely a problem. It is nonetheless a noteworthy feature
and may influence the choice of valve. TOE is also able to
observe bulky and friable complex atheromatous plaques
in the ascending aorta. These may impede the passage of
the delivery system or result in complications.
Measurements of the aortic sinuses, sinotubular junction
and ascending and descending aorta on CT can also be
made, and the extent of atherosclerotic plaque is likely
associated with complications including stroke [81, 82].
Fig. 1 Flow diagram outlining
the role of echocardiographic
assessment of aortic stenosis in
the workup prior to TAVI
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A flow diagram describing the echocardiographic assess-
ment of aortic stenosis prior to TAVI is detailed in Fig. 1.
Conclusions
The development of transcatheter aortic valve implantation
has been a seismic change in the management of aortic steno-
sis as an alternative intervention to surgical aortic valve re-
placement in appropriately selected patients. Selection of pa-
tients prior to TAVI requires optimal imaging, and although
2D TTE is the initial modality of choice, there may be cases
where TOE where may required. Confirming the sever-
ity of aortic stenosis and the presence of concomitant
factors such as mitral regurgitation and pulmonary hy-
pertension is usually performed by TTE. However, the
aortic valve is a complex structure and 3D echocardiog-
raphy and CT are the preferred imaging modalities for
assessing the anatomy and annular dimensions prior to
TAVI and have been shown to change valve sizing strat-
egy compared with 2D echo.
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